1. Introduction
===============

Acute respiratory tract infection is a leading cause of paediatric morbidity and mortality ([@bib17]). Well recognized viral agents traditionally associated with respiratory tract infections are respiratory syncytial virus (RSV), influenza viruses A and B, parainfluenza viruses (PIV) 1--3, and adenoviruses (Adv). Since 2001, improved virus discovery techniques have seen to the identification of several new viruses associated with acute respiratory tract infections including human metapneumovirus (hMPV) ([@bib26]), human coronaviruses (hCoV) HKU1 ([@bib33]) and NL63 ([@bib27]), and human bocavirus (hBoV) ([@bib2]). At present, the most commonly used technique for the diagnosis of viral respiratory tract infections is cell culture usually in combination with direct immunofluorescence assays (IFA) ([@bib6]). Nucleic acid detection methods have recently become more readily available for the diagnosis of virus infections ([@bib29]). Comparative studies have shown that for the detection of respiratory viruses real-time RT-PCR is significantly more sensitive than conventional detection methods ([@bib8], [@bib13], [@bib21], [@bib25]). The majority of real-time RT-PCR detection assays for respiratory viruses are only qualitative of nature. Even though qualitative real-time PCR in the diagnostic setting has numerous advantages over more traditional detection methods, one of the limitations is that it does not discriminate between current infections or shedding of low concentration of virus from previous infections. The significance of co-infections is also not portrayed. In contrast, quantitative real-time PCR provides qualitative as well as quantitative information. The advantages of quantitative real-time PCR are that it permits the assessment of viral load at a given time point, facilitates the monitoring of response to treatment, and offers the possibility to determine the dynamics of virus proliferation ([@bib29]). Quantitative tests may aid in the study of virus pathogenesis, development of vaccine and antiviral strategies, and will facilitate investigations of the importance of respiratory viruses when detected by themselves or as co-infections in patients.

Qualitative detection of viral respiratory pathogens by multiplex real-time PCR has been described previously ([@bib4], [@bib9], [@bib23]). These studies employ the use of hydrolysis probes ([@bib4], [@bib9]) and molecular beacons ([@bib23]) as probe chemistry which are highly sensitive to hybridization mismatches. Due to the high mutation frequencies of respiratory viral genomes this may result in false negative results ([@bib10]). In contrast, fluorescence resonance energy transfer (FRET) hybridization probes can tolerate up to 6 mismatches ([@bib34]). In addition, the probes are not hydrolyzed during the amplification reaction, thereby facilitating generation of amplicon-specific melting curves for further discrimination and incorporation of multiple targets per reaction.

In this study, the development and application of a novel quantitative real-time RT-PCR assay utilizing FRET probes for the differential diagnosis of well recognized and new respiratory viruses are described. This consisted of four multiplex reactions covering 13 different viruses that may be run individually or concurrently.

2. Materials and methods
========================

2.1. Viruses and clinical specimens
-----------------------------------

Tissue culture positive controls were available for RSV subtype A and B, PIV 1--3, influenza A and B, and adenovirus. Clinical specimens that tested positive by PCR for hMPV, hCoV-NL63 and hCoV-OC43 were obtained from Dr. Jan Kimpen, University of Utrecht, The Netherlands, and hBoV from Dr. Heidi Smuts, University of Cape Town, South Africa, while RNA from positive clinical specimens for hCoV-HKU1 and hCoV-229E were obtained from Dr. Astrid Vabret, University Hospital of Caen, France. For the validation of the multiplex assays, 91 respiratory specimens that previously tested positive for each virus were also collected. In addition, respiratory specimens (*n*  = 270) that tested negative for respiratory viruses by direct immunofluorescence with the Light Diagnostics™ Respiratory Panel 1 Viral Screening and Identification Kit for RSV A and B, PIV 1, 2, and 3, Influenza A and B, and Adenovirus (Millipore, USA) or the rapid BD Directigen™ RSV test (BD, Franklin Lakes, NJ, USA) were collected over 1 year by the Department of Medical Virology, University of Pretoria/National Health Laboratory Services Tshwane Academic Division. Specimens included nasopharyngeal aspirates, bronchoalveolar lavage specimens, endotracheal aspirates, and sputum specimens.

2.2. Processing of specimens
----------------------------

Upon receipt phosphate buffered saline (PBS) was added to all nasopharyngeal aspirates to a final volume of 1 ml before vortexing the specimen and clarifying it of cells and mucus at 3000 ×  *g* for 5 min. Supernatants were removed and stored at −70 °C for PCR analysis.

2.3. RNA extraction
-------------------

Nucleic acids from cultured virus controls were extracted from 200 μl cell culture fluid using the High Pure PCR Template Kit (Roche, Mannheim, Germany), according to manufacturer\'s instructions. Total nucleic acids from clinical specimens were extracted from 200 μl clarified nasopharyngeal aspirate with the automated MagNA Pure Nucleic Acid Isolation System (Roche, Mannheim, Germany), using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche, Mannheim, Germany), according to the manufacturer\'s instructions. Negative water controls were included in every run.

2.4. Primer and probe design
----------------------------

For each virus, multiple sequence alignments of all known strains identified by BLAST search analysis were performed in ClustalX (version 1.81) ([@bib24]), and conserved regions identified for primer and probe design. Primers were designed using Primer3 ([@bib19]) to have melting temperatures of ∼60 °C. FRET probes were designed with the support of TIBMOL Biological (Berlin, Germany) and were evaluated using the Light Cycler Probe Design Software 2.0 (version 1.0) on site. The layout of the multiplex assays including primer and probe sequences is indicated in [Table 1](#tbl1){ref-type="table"} . Serving as an internal control and reference gene in each multiplex reaction, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was targeted with a separate primer--probe set and individually detected at wavelength of 705 nm.Table 1Design of the multiplex real-time RT-PCR multiplex assays indicating the viruses covered by each of the four multiplex reactions as well as the genes that the primer and probes target and the wavelength where they can be detected.MultiplexTargetPrimerSequence (5′--3′) \[concentration in nM\]GeneAuthors (Ref.)1Respiratory syncytial virusSense primerATG GCT CTT AGC AAA GTC AA \[800 nM\]NucleoproteinThis studyAntisense primer 1TTC TGC ACA TCA TAA TTA GGA G \[400 nM\][@bib9]Antisense primer 2TTT TGC ACA TCA TAA TTG GGA GT \[400 nM\]This study**Donor probeAAT GAT ACA CTG TCA TCC AGC AAA TAC AC-FL**[a](#tbl1fn1){ref-type="table-fn"}This study**Acceptor probe 1**[b](#tbl1fn2){ref-type="table-fn"}**LCRed610-TTC AAC GTA GTA CAG GAG ATA ATA TTG-PH**[c](#tbl1fn3){ref-type="table-fn"}This study**Acceptor probe 2LCRed610-TCC AAC GGA GCA CAG GA-PH**This study  Human metapneumovirusSense primerCAA CTG TTT ACT ACC CAA ATG A \[300 nM\]Fusion proteinThis studyAntisense primerATA GGG TGT CTT CCT GTG C \[300 nM\]This study**Donor probeTGT TGC ATT CCY TTG AYT GCT CAG CAA C-FL**This study**Acceptor probeLCRed640-TTG ATM CCW GCT GCT GTG TCG CA-PH**This study  Human bocavirusSense primerGGG TGT GTT AAT CAT TTG AAC \[400 nM\]NS1 proteinThis studyAntisense primerCAC TGT CTC TAT GCT TGA CG \[400 nM\]This study**Donor probeCTT TGC AGG TTC CAC CCA ATC C-FL**This study**Acceptor probeLCRed670-TGC ATT AAG CAC TCC TCC CAC CAA-PH**This study  2Parainfluenza virus type 1Sense primerTAT CAA TTG GTG ATG CAA TAT AT \[300 nM\]HemagglutininThis studyAntisense primerTCC TGT TGT CGT TGA TGT C \[300 nM\]NeuraminidaseThis study**Donor probeTAA CCT AAT TgT AAA ACC TgC CCT ATA TCT-FL**This study**Acceptor probeLCRED 610-CAC ATC CTT GAG TGA TTA AGT TTG ATG AAT-PH**This study  Parainfluenza virus type 2Sense primerCCA TTT ACC TAA GTG ATG GAA T \[300 nM\]HemagglutininThis studyAntisense primerATG AGA CCA CCA TAT ACA GGA \[300 nM\]NeuraminidaseThis study**Donor probeGAT CTA GCT GAA CTG AGA CTT GCT TTC TAT T-FL**This study**Acceptor probeLCRed 610-TGA TAC CTT TAT TGA AAG AGT CAT ATC TCT TCC-PH**This study  Parainfluenza virus type 3Sense primer**TGT ATT TAT CAA AGG GAC CAC** \[300 nM\]NucleoproteinThis studyAntisense primer**TCC AGA TAT GAT CTT CCC GTC** \[300 nM\]This study**Donor probeCAT ACA TGG TGA GTT CGC ACC AG-FL**This study**Acceptor probeLCRed640-CAA CTA TCC TGC CAT ATG GAG YTA TGC-PH**This study  Human coronavirus NL63Sense primerATA AAC TTG ATA CTG GTG CAC AA \[400 nM\]ORF1aThis studyAntisense primerTCT AAT GTT ATA CTT AAA ACT ACG TGT C \[400 nM\]This study**Donor probeCTA TTA TGA AGC ATG ATA TTA AAG TTA TTG CC-FL**This study**Acceptor probeLCRed670-AGG CTC CTA AAC GTA CAG GTG TTA TTT-PH**This study  3Influenza A[d](#tbl1fn4){ref-type="table-fn"}Sense primerGAC CRA TCC TGT CAC CTC TGA C \[1000 nM\]NS1 proteinWHO recommended[d](#tbl1fn4){ref-type="table-fn"}Antisense primerAGG GCA TTY TGG ACA AAK CGT CTA \[1000 nM\]WHO recommended[d](#tbl1fn4){ref-type="table-fn"}**Donor probeGGG ATT TTR GGR TTT GTG TTC ACG CTC ACC-FL**This study**Acceptor probeLCRed 610-CCC AGT GAG CGA GGA CTG CAG C-PH**This study  Influenza BSense primer**AGA GTT GGA CTT GAY CC** \[300 nM\]Nucleoprotein[@bib21]Antisense primer**CAT AGG CAG TCT TGG CT** \[300 nM\][@bib21]**Donor probeGGA AGC ACA MTC CCC AGA AGA TCA GGT-FL**[@bib21]**Acceptor probeLCRed640-AAC TGG TGT TGC GAT CAA AGG AGG TGG-PH**[@bib21]  AdenovirusSense primerGCC CCA GTG GKC TTA CAT GCA CAT C \[300 nM\]Hexon protein[@bib11]Antisense primerGCC ACG GTG GGG TTT CTA AAC TT \[300 nM\][@bib11]**Donor probe 1AAC TGC ACC AGA CCC GGA C-FL**This study**Acceptor probe 1LCRed670-AGG TAC TCC GAA GCA TCC TGT CC-PH**This study**Donor probe 2AAC TGC ACC AGC CCG GG-FL**This study**Acceptor probe 2LCRed670-AGG TAC TCC GAG GCG TCC TGG-PH**This study  4Human coronavirus OC43Sense primerCAT GCA ATG GCA ATA AGA T \[400 nM\]ORF1bThis studyAntisense primerTTG AAA GGC ACT TAT ATT AGC A \[400 nM\]This study**Donor probeCAA AGG TTG AAT CAA CCT TAT CAC TTC T-FL**This study**Acceptor probeLCRed610-CAC ATG TGA GTA TAA GCG CTT CTG AAG-PH**This study  Human coronavirus HKU1Sense primerTTG TTG TTC ACA TGG TGA TAG \[500 nM\]ORF1bThis studyAntisense primerTTG CGT ATA CTT AAA TCT TCA ATC \[500 nM\]This study**Donor probeCTG CTA GTA CCA CCA GGC TTA ACA T-FL**This study**Acceptor probeLCRed640-AGC AAC CGC CAC ACA TAA CTA TTT CA-PH**This study  Human coronavirus 229ESense primerCTC AAT CTC GGA ATC CTT C \[300 nM\]NucleoproteinThis studyAntisense primerCTC TGA GAA CGA GCA AGA CT \[300 nM\]This study**Donor probeGGG TAC TCC TAA GCC TTC TCG TAA TCA-FL**This study**Acceptor probeLCRed670-TCC TGC TTC TTC TCA AAC TTC TGC C-PH**This study[^1][^2][^3][^4]

2.5. Real-time RT-PCR
---------------------

cDNA was synthesized using Expand Reverse Transcriptase (Roche, Mannheim, Germany), according to the manufacturer\'s instructions. Real-time PCR reactions were performed using the Light Cycler FastStart DNA Master^PLUS^ HybProbe Kit (Roche, Mannheim, Germany) and contained 4 μl of 5× Master Mix, 100 nM of each probe, variable concentrations of primers (indicated in [Table 1](#tbl1){ref-type="table"}), and 5 μl of cDNA reaction mixture as template in a final volume of 20 μl. Real-time PCR cycling was performed on a Light Cycler 2.0 (Roche, Mannheim, Germany) as follows: 95 °C for 10 min followed by 45 cycles of 95 °C for 10 s, 58 °C for 8 s, 54 °C for 8 s, 50 °C for 2 s (ramp rate 5 °C/s), and 72 °C for 11 s, followed by melting curve analysis at 95 °C for 10 s, 40 °C for 30 s and 80 °C for 0 s (ramp rate 0.1 °C/s).

2.6. DNA sequencing
-------------------

PCR amplicons for DNA sequencing were gel purified using the Wizard^®^ SV Gel and PCR Clean-Up System (Promega, Madison, WI, USA), according to the manufacturer\'s instructions. DNA sequencing was performed with specific primers using the ABI PRISM BigDye Terminator Cycle Sequencing Reaction Kit (version 3.1) on an ABI PRISM 3130 DNA sequencer (Applied Biosystems, Foster City, CA, USA), according to the manufacturer\'s instructions.

2.7. Quantitation of viral loads
--------------------------------

### 2.7.1. RNA standards for quantitation

Target regions for each respective virus and the internal control (GAPDH) were amplified with the Expand High Fidelity PCR Kit (Roche, Mannheim, Germany) using specific primers. Amplicons were gel purified using the Wizard^®^ SV Gel and PCR Clean-Up System (Promega, Madison, WI, USA) and cloned into the pJET1.2/blunt cloning vector (Fermentas, Ontario, Canada) according to the manufacturer\'s instructions.

### 2.7.2. In vitro transcription

In vitro transcription was performed with the TranscriptAid™ T7 High Yield Transcription Kit (Fermentas, Ontario, Canada), according to the manufacturer\'s instructions. Plasmid DNA was removed by addition of 2 U of DNase I at the end of the reaction and incubated at 22 °C for 8 h. RNA was purified with the RNeasy Plus Mini Kit (Qiagen, Hamburg, Germany) and the concentration determined with the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) at 260 nm.

2.8. Analytical sensitivity of multiplex assays
-----------------------------------------------

The detection limits of the multiplex assays were determined by testing 10-fold serial dilutions of the quantified RNA transcripts. Detection of each dilution was performed in triplicate. The detection limit was defined as the lowest concentration where all three replicates could be detected. For DNA viruses dilution series of plasmid DNA was used.

2.9. Statistical analyses
-------------------------

The confidence level of data analysed was determined with the Student\'s *t*-test with two-tailed distribution.

3. Results
==========

3.1. Multiplex development
--------------------------

Optimization of the multiplex assays was done on culture controls or on specimens that previously tested positive by PCR in independent laboratories. The newly designed real-time RT-PCR assays were initially optimized as monospecific assays. To assess the specificity of the primers and probes, the assays were tested for cross-reactivity among the 13 viruses using control specimens with viral loads of approximately 1 × 10^7^--1 × 10^9^ copies/ml. In all cases each virus was only detected by its specific primer and probe set, no cross-reaction was observed. The monospecific assays were subsequently combined to form four multiplex assays comprising of the following viruses: Multiplex 1---RSV A and B, hMPV, hBoV; Multiplex 2---parainfluenza virus (PIV) 1, 2, and 3, hCoV-NL63; Multiplex 3---influenza A and B, adenovirus; Multiplex 4---hCoV-OC43, hCoV-HKU1, and hCoV-229E. Viruses were combined into the various multiplex assays according to shared similarities in clinical manifestations and susceptible age groups. The sensitivity of the assays was determined in triplicate through the amplification of serially diluted in vitro transcribed RNA from cloned controls. Detection limits for RNA viruses ranged from 2.5 to 25 in vitro transcribed RNA copies/μl (corresponds to 2.5 × 10^3^--2.5 × 10^4^ copies/ml of specimen) and 25 plasmid DNA copies/μl for DNA viruses (corresponds to 2.5 × 10^4^ copies/ml of specimen) ([Table 2](#tbl2){ref-type="table"} ). Lower concentrations were detected, however, at these concentrations detection of all replicates could not be achieved and was therefore not considered true detection limits. To assess the inter-run precision of the respective assays, extraction and real-time RT-PCR detection were performed on triplicate aliquots from viral suspensions. Three independent real-time RT-PCR runs performed showed a coefficient of variation of between 0.03% and 3.05% ([Table 2](#tbl2){ref-type="table"}), indicating high reproducibility of the real-time RT-PCR assays. All four multiplexes were optimized to be performed under the same cycling conditions for simultaneous use. In the event that a 60-nt conserved region could not be identified, a technique described by [@bib18] was used to overcome this. This technique was applied to probes used for the detection of RSV A and B, and PIV-2.Table 2Validation of multiplex real-time RT-PCR assays on 91 known positive clinical specimens.Virus and method of control detectionNumber of known positive clinical samplesSamples detected with multiplex assaysDetection limitInter-run coefficient of variation (%)Direct immunofluorescence assay (IFA) RSV30302.5 RNA copies/μl0.42 PIV 1882.5 RNA copies/μl0.31 PIV 21[a](#tbl2fn1){ref-type="table-fn"}12.5 RNA copies/μl1.46 PIV 38825 RNA copies/μl0.91 Influenza A8825 RNA copies/μl0.29 Influenza B4425 RNA copies/μl0.44 Adv5525 DNA copies/μl0.38  PCR hMPV772.5 RNA copies/μl3.05 hCoV-NL63552.5 RNA copies/μl0.21 hCoV-HKU1112.5 RNA copies/μl0.03 hCoV-OC43442.5 RNA copies/μl2.93 hCoV-229E112.5 RNA copies/μlNot done[b](#tbl2fn2){ref-type="table-fn"}  Nested PCR hBoV95[c](#tbl2fn3){ref-type="table-fn"}25 DNA copies/μl1.14[^5][^6][^7]

To determine if amplification competition may lead to interference during simultaneous quantitation of more than one virus in a single reaction, quantified controls were added together at varying concentrations and quantified concurrently. The results indicated that simultaneous quantitation of two viruses with varying concentrations \>2.5 × 10^4^ copies/ml (i.e. detected before amplification cycle 28), showed a coefficient of variation of \<3.5%, indicating that the multiplex assays can accurately quantify two viruses in a single reaction. However, when a second virus is detected after amplification cycle 28 (i.e. virus concentration \<2.5 × 10^4^ copies/ml) or a third virus was present, accurate quantitation of viral load could not be achieved. In these events the viruses will have to be quantified separately to ensure accurate quantitation of viral load. However, for diagnostic purposes simultaneous qualitative detection of more than one virus can be achieved to a detection limit of approximately 2.5 × 10^4^ copies/ml.

3.2. Evaluation of multiplex assays
-----------------------------------

### 3.2.1. Clinical evaluation

The multiplex assays were validated on a total of 91 clinical specimens that previously tested positive for the presence of respiratory viruses by IFA, PCR or semi-nested PCR. With the exception of hBoV, that was only detected in 5/9 specimens, viruses were detected in all the known positive specimens evaluated ([Table 2](#tbl2){ref-type="table"}). HBoV was previously identified in the positive control specimens by semi-nested PCR. In 4/9 specimens hBoV could not be detected by a single-round PCR. The detection limit of bocavirus by the real-time PCR is 25 copies/μl (2.5 × 10^4^ copies/ml of specimen), suggesting high sensitivity although this is not as sensitive as the conventional semi-nested PCR by which it was initially detected ([@bib22]). Application of the quantitative feature of this assay was demonstrated on RSV positive specimens from 32 children with mild disease (infants who visited outpatients but did not require hospitalization) and 26 children with severe disease (patients admitted to the intensive care unit) ([Table 3](#tbl3){ref-type="table"} ). An association between higher viral loads and severe disease is demonstrated as the RSV viral load in patients with severe disease was significantly higher (*p*  = 0.014) (mean: 3.35 × 10^10^ copies/ml, median 6.04 × 10^9^ copies/ml) compared to patients with mild disease (mean: 3.44 × 10^9^ copies/ml, 7.4 × 10^8^ copies/ml). The internal control (GAPDH) was continuously detected in all supernatant fractions at concentrations ranging between 1.59 × 10^5^ and 1.41 × 10^9^ copies/ml of processed specimens (mean: 2.69 × 10^8^ copies/ml, median: 1.03 × 10^8^ copies/ml), confirming its value as a nucleic acid extraction control.Table 3Calculation of viral load in single RSV infected patients with mild and severe respiratory tract disease.Mild disease (*n* = 32)Severe disease (*n* = 26)*p* (95% CI)Mean3.44 × 10^9^3.35 × 10^10^0.014Median7.40 × 10^8^6.04 × 10^9^Range638--2.9 × 10^10^3.98 × 10^3^--1.77 × 10^11^

### 3.2.2. IFA negative specimen screening

Real-time RT-PCR screening of 270 respiratory specimens negative for the respiratory viruses targeted by routine IFA identified new viruses in 40/270 (14.8%) cases as well as 79/270 (29.3%) additional well recognized viruses previously missed by routine IFA ([Table 4a](#tbl4){ref-type="table"} ). Human bocavirus (*n*  = 14), human metapneumovirus (*n*  = 15), and human coronavirus NL63 (*n*  = 5) were detected in the IFA negative group. Although hCoV-HKU1 and hCoV-229E were not detected in the IFA negative specimen group, both were detected as co-infections in the IFA positive control specimens, hCoV-HKU1 as a co-infection with PIV 3 and hCoV-229E occurred as a co-infection with RSV. In addition, 79 (29.3%) of the IFA negative specimens tested positive for viruses already included in the IFA panel, suggesting a marked improved sensitivity over the IFA. To rule out the possibility of false positive results, one-third of all amplicons were randomly selected and sequenced to confirm the specificity of the assay. All sequencing reactions were successful. Non-specific detection was not observed. Co-infections were detected in 6.7% of specimens ([Table 4a](#tbl4){ref-type="table"}, [Table 4b](#tbl5){ref-type="table"} ). Viral loads were quantified where co-infections occurred with hMPV, hBoV and coronaviruses ([Table 4b](#tbl5){ref-type="table"}), though the clinical relevance of these findings will be described elsewhere. Viruses could be detected in all the different types of respiratory specimens (nasopharyngeal aspirate specimens, bronchoalveolar lavage specimens, endotracheal aspirate specimens, and sputum specimens).Table 4aAdditional respiratory viruses detected in 270 respiratory specimens that tested negative by routine diagnostic assays.VirusNumber of detectionsNumber of co-infections (%)**Viruses routinely screened for by IFA panel**RSV356 (17.1%)PIV 121 (50%)PIV 231 (33%)PIV 3142 (14.3%)Influenza A42 (50%)Influenza B30Adv187 (38.9%)  Total79 (29.3%)  **Viruses not in routine diagnostic assays**hMPV144 (28.6%)hBoV158 (53.3%)hCoV-NL6354 (80%)hCoV-HKU100hCoV-229E00hCoV-OC4365 (83.3%)  Total40 (14.8%)Table 4bCombination of respiratory virus co-infections as identified and quantified by multiplex real-time RT-PCR.Co-infecting virusesNumber of detectionsQuantification of co-infections (copies/ml)**Double infections**Adv + hCoV-OC432Adv: 2.78 × 10^4^ and 3.35 × 10^4^; hCoV-OC43: 2.80 × 10^4^ and 5.48 × 10^7^Adv + hBoV2Adv: 3.53 × 10^5^ and 7.40 × 10^3^; hBoV: 3.58 × 10^6^ and 6.10 × 10^4^hBoV + hMPV2hBoV: 5.98 × 10^6^ and 3.35 × 10^9^; hMPV: 1.45 × 10^7^ and 2.33 × 10^9^Adv + RSV1Not determinedhBoV + hCoV-NL631hBoV: 5.28 × 10^6^; hCoV-NL63: 1.21 × 10^6^hBoV + hCoV-OC431hBoV: 4.30 × 10^9^; hCoV-OC43: 1.58 × 10^6^hBoV + PIV31hBoV: 2.30 × 10^6^; PIV3: 8.38 × 10^9^hCoV-OC43 + PIV11hCoV-OC43: 3.43 × 10^5^; PIV1: 2.58 × 10^4^hCoV-OC43 + PIV21hCoV-OC43: 4.35 × 10^4^; PIV2: 4.20 × 10^6^hCoV-NL63 + RSV1hCoV-NL63: 2.50 × 10^5^; RSV: 4.15 × 10^8^hMPV + RSV1hMPV: 1.03 × 10^5^; RSV: 1.30 × 10^11^Influenza A + PIV31Not determinedInfluenza A + RSV1Not determined  **Triple infections**hBoV + hMPV + hCoV-NL631hBoV: 3.23 × 10^9^; hMPV: 1.36 × 10^6^; hCoV-NL63: 8.15 × 10^6^Adv + RSV + hCoV-NL632Adv: 1.34 × 10^4^; RSV: 9.53 × 10^8^; hCoV-NL63: 8.00 × 10^5^Adv: 3.75 × 10^3^; RSV: 9.83 × 10^5^; hCoV-NL63: 3.75 × 10^3^

3.3. Identification of nucleotide base changes
----------------------------------------------

Melting curve analysis of RSV positive clinical specimens revealed four distinct melting curves with melting temperatures (*T* ~m~) of 59 °C, 54 °C, 51 °C, and 47 °C ([Fig. 1](#fig1){ref-type="fig"} ) identified in 100/131 (76.3%), 20/131 (15.3%), 4/131 (3.1%), and 7/131 (5.3%) of RSV infected patients, respectively. Sequencing of the RSV target regions identified the presence of single base mutations in the region where the probe hybridized to the template ([Fig. 1](#fig1){ref-type="fig"}) despite complete conservation in specimen sequences on GenBank in this area. This confirms the robustness of the FRET hybridization probe technology to tolerate mismatches and overcoming variability of RNA viruses.Fig. 1Melting curve analysis illustrating the detection of four different RSV A strains identified with the RSV specific fluorescence resonance energy transfer (FRET) hybridization probes. Comparison of the nucleotide sequences of the RSV A strains relative to a reference strain (RSV A\*, GenBank accession number [X00001](ncbi-n:X00001)) indicating the single nucleotide mismatches corresponding to the four different melting curve profiles. Dots indicate conserved bases, whereas sequence variations are indicated by the nucleotide base.

RSV (*T* ~m~)59 °C-strains were detected in 53/100 (53%) hospitalized patients, whereas RSV (*T* ~m~)54 °C-, (*T* ~m~)51 °C-, and (*T* ~m~)47 °C-strains were associated with slightly higher hospitalization rates with 15/20 (75%), 4/4 (100%), and 5/7 (71.4%), being detected in hospitalized patients. It is however unlikely that single base changes in the nucleoprotein will influence disease severity, though further investigations will follow. Melting curve analysis revealed no difference in *T* ~m~s for any of the other viruses detected by the multiplex assays.

4. Discussion
=============

In this study we described the development of four quantitative multiplex real-time RT-PCR assays that can be run concurrently for the detection of 13 respiratory viruses. For the detection of respiratory viruses targeted by routine IFA, the multiplex assays were shown to be as specific as the routinely used commercial IFA but also to be significantly more sensitive, increasing the detection of these viruses by 29.3%. Inclusion of the additional respiratory viruses in the detection assay increased the overall detection frequency by a further 9.7%. Discrepant results in the study may be attributable to the increased sensitivity of real-time PCR. For the detection of RSV, a previous study reported 50--90% of specimens positive by PCR but negative by IFA had viral loads less than 1 × 10^6^ copies/ml, suggesting a lower limit of sensitivity for IFA in this range ([@bib14]). In this study, the assay demonstrated a detection limit ranging between 2.5 × 10^3^ and 2.5 × 10^4^ copies/ml, which is \>2 logs lower than the approximate IFA detection limit. These detection limits should be fitting for the detection of respiratory viruses, as previously reported viral loads in respiratory specimens ranged between 1 × 10^3^ and 1 × 10^11^ copies/ml ([@bib13]). Viral loads less than 1 × 10^3^ copies/ml have been described, though the clinical relevance at such low levels has been questioned ([@bib1], [@bib28]).

Respiratory specimens are non-homogenous and may vary in consistency (degree of viscosity due to the presence of mucous), volume, and manner of collection, thus making quantitative analysis of respiratory specimens methodically difficult. Since respiratory specimens are difficult to standardise, quantitation of respiratory viruses by PCR is better described as semi-quantitative ([@bib20]). In this study, semi-quantitative results of RSV positive patients with mild and severe disease demonstrated a significantly higher RSV viral load in patients with severe disease confirming the relevance of this feature and confirms previous findings for RSV ([@bib5], [@bib7], [@bib15]). Continuous detection of the internal control (GAPDH) indicated that quantitation was not influenced by poor RNA extraction or PCR inhibitors.

In comparison to conventional detection methods, real-time probe based PCR assays have been shown to detect respiratory viruses with increased sensitivity and specificity ([@bib8], [@bib13], [@bib21], [@bib25]). A pitfall of real-time PCR is that the more commonly used probe chemistries (hydrolysis probes and molecular beacons) are highly sensitive to mismatches, which may lead to false negative results if point mutations occur ([@bib10]). In contrast, the assays described in this study utilize two FRET hybridization probes which have the advantage of being able to tolerate a greater number of mismatches than hydrolysis probes or molecular beacons, decreasing the occurrence of false negative results substantially. The benefit of FRET probes was illustrated here; where point mutations were detected in the sites where the probe hybridized to the target template in several clinical specimens despite complete conservation of this area on GenBank. An obstacle when designing FRET hybridization probes is that a conserved area of approximately 60 nt is needed for the two probes to bind. In highly variable virus genomes this might pose a problem. However, this can be overcome by using an oligonucleotide probe complementary to conserved regions flanking a variable region as described by [@bib18]. Binding of the probe brings the two conserved regions together, resulting in the variable region to loop out, thereby omitting variable sequences. If a 60-nt conserved region could not be identified, as was the case for RSV and PIV 2, this technique was successfully applied to overcome this complication.

In addition to being highly sensitive and specific, the assay has a turnaround time of \<3 h and covers 13 viruses. The test is currently optimized for the Light Cycler 2 but could be transferred to the Light Cycler 480 for 96-well format. For paediatric patients, rapid diagnosis of respiratory tract infections can lead to improved management and reduce unnecessary antibiotic use and length of hospitalization ([@bib3], [@bib32]). Rapid diagnosis is also imperative in managing nosocomial spread of respiratory viruses to high risk patients e.g. bone marrow transplant patients and cancer recipients ([@bib12], [@bib16], [@bib30], [@bib31]). In addition, the quantitative application of the assay will contribute to addressing questions on viral pathogenesis and may facilitate investigations of the importance of hMPV, hBoV and coronaviruses when detected by themselves or as co-infections in patients.

In conclusion, the findings of the study demonstrate the application of the multiplex real-time PCR assays with FRET hybridization probes to detect respiratory viruses and the associated viral load. The assays may facilitate studies of virus pathogenesis and facilitate investigations of the importance of the respiratory viruses recently identified as causes of acute respiratory tract infections, but also confirm the relevance of a positive PCR finding in acute disease.
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[^1]: The donor fluorophore, fluorescein (FL).

[^2]: The acceptor fluorophore. The number following LCRed is the wavelength at which fluorescence is emitted.

[^3]: Phosphate (PH) on 3′-end to prevent extension of probe by DNA polymerase.

[^4]: These primers were substituted with the WHO primers that detect all influenza A strains, including novel influenza A H1N1 and corresponding probes designed. Testing on seasonal H3N2, H1N1 and novel H1N1 confirmed the specificity of the new probes.

[^5]: Only one clinical specimen was available for validation of this virus. However, in addition, three PIV 2 positive specimens that previously tested negative by routine immunofluorescence were detected in the negative specimen screen.

[^6]: Due to limited sample volume the inter-assay coefficient of variation for hCoV-229E could not be determined.

[^7]: In 4 specimens, hBoV could only be detected by semi-nested PCR.
